SARS-COV coronavirus S2 protein polypeptide and application thereof
The invention relates to an SARS-COV coronavirus S2 protein polypeptide and an application thereof. Specifically, a section of specific S2 protein antigen epitope shown as SEQ ID No.1 is found, antiserum is prepared through the epitope, and it is shown that the obtained antibody has good titer and has an immune protection effect on SARS-CoV attack..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 01. Sept. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU LI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-09-01, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111606980 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006537693 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006537693 | ||
| 003 | DE-627 | ||
| 005 | 20230504073706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA006537693 | ||
| 035 | |a (EPA)CN111606980 | ||
| 035 | |a (EPA)72204922 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU LI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-COV coronavirus S2 protein polypeptide and application thereof |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-09-01, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 | ||
| 520 | |a The invention relates to an SARS-COV coronavirus S2 protein polypeptide and an application thereof. Specifically, a section of specific S2 protein antigen epitope shown as SEQ ID No.1 is found, antiserum is prepared through the epitope, and it is shown that the obtained antibody has good titer and has an immune protection effect on SARS-CoV attack. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 01. Sept. |
| 773 | 1 | 8 | |g year:2020 |g day:01 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72204922/publication/CN111606980A1?q=CN111606980 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 01 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 01 |c 09 | ||